TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Nicotine Replacement Therapy Responder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patches | Arm Label: Pre-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit) | Arm Label: Pre-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Pre-Quit) | Arm Label: Pre-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Pre-Quit) | Arm Label: Post-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit) | Arm Label: Post-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Post-Quit) | Arm Label: Post-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Post-Quit) | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Replacement Therapy Responder | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Nicotine
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Healthy Volunteers; Type: N/A; Interventions: N/A | Arm Label: Patients; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Web + Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Web + Phone | Arm Label: Web Only; Type: EXPERIMENTAL; Interventions: Behavioral: Web Only | Arm Label: Phone Only; Type: EXPERIMENTAL; Interventions: Behavioral: Phone Only | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Web + Phone; Assigned to Arm(s): Web + Phone | Intervention Type: BEHAVIORAL; Name: Web Only; Assigned to Arm(s): Web Only | Intervention Type: BEHAVIORAL; Name: Phone Only; Assigned to Arm(s): Phone Only | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/Low Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/Low Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/High Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/High Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Intervention Type: DRUG; Name: Bupropion and NRT; Assigned to Arm(s): Brief Treatment, Extended Bupropion/High Contact, Extended Bupropion/Low Contact, Extended Placebo/High Contact, Extended Placebo/Low Contact
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
B: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).
Brief Summary: The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.


Options:
A: Arm Label: Tolterodine ER; Type: EXPERIMENTAL; Interventions: Drug: Tolterodine ER | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): Tolterodine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vibegron + Placebo to match Tolterodine; Type: EXPERIMENTAL; Interventions: Drug: vibegron, Drug: Tolterodine placebo | Arm Label: Placebo to match vibegron + Placebo to match Tolterodine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine placebo | Arm Label: Tolterodine + Placebo to match vibegron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vibegron placebo, Drug: Tolterodine Tartrate ER | Intervention Type: DRUG; Name: vibegron; Assigned to Arm(s): Vibegron + Placebo to match Tolterodine | Intervention Type: DRUG; Name: Vibegron placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine Tartrate ER; Assigned to Arm(s): Tolterodine + Placebo to match vibegron | Intervention Type: DRUG; Name: Tolterodine placebo; Assigned to Arm(s): Placebo to match vibegron + Placebo to match Tolterodine, Vibegron + Placebo to match Tolterodine
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: solifenacin | Arm Label: Solifenacin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: solifenacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Solifenacin 5 mg | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 5 mg
D: Intervention Type: DRUG; Name: tolterodine SR, overactive bladder; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-year Randomised Double-blind Placebo-controlled International Multicentre Study.
Brief Summary: The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function.


Options:
A: Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): N/A
B: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ivabradine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivabradine | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Active arm, Placebo arm
C: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm
D: Arm Label: Ivabradine; Type: EXPERIMENTAL; Interventions: Drug: Ivabradine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Ivabradine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome After Symptomatic Proximal Deep Venous Thrombosis
Brief Summary: The purpose of this study is to determine whether elastic compression stockings used for 2 years are effective in preventing the post-thrombotic syndrome in patients with symptomatic proximal deep venous thrombosis.


Options:
A: Arm Label: Apixaban Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban 2.5 MG | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban 2.5 MG; Assigned to Arm(s): Apixaban Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome After Symptomatic Proximal Deep Venous Thrombosis
Brief Summary: The purpose of this study is to determine whether elastic compression stockings used for 2 years are effective in preventing the post-thrombotic syndrome in patients with symptomatic proximal deep venous thrombosis.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I
C: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS
D: Intervention Type: DEVICE; Name: Elastic stockings; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome After Symptomatic Proximal Deep Venous Thrombosis
Brief Summary: The purpose of this study is to determine whether elastic compression stockings used for 2 years are effective in preventing the post-thrombotic syndrome in patients with symptomatic proximal deep venous thrombosis.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS

Answer: D